PEDIJATRIC ASPECTS OF SACCHAROMYCES BOULARDI IN SERBIA
DOI:
https://doi.org/10.46793/PP170305015SKeywords:
Saccharomyces boulardii, child, probioticAbstract
Introduction. In pediatric practice, the most commonly used probiotics that contain the fungus Saccharomyces boulardii and bacteria from the group Lactobacillus or Bifidobacterium. Guidelines for the use of probiotics on children recommend the use of Saccharomyces boulardii in acute gastroenteritis, eradication of Helicobacter pylori infections, prevention of diarrhea associated with antibiotics and Clostridium difficile enterocolitis.
Objective. The aim of this study was to examine the use of modern aspects Saccharomices Boulardii (Bulardi® Junior Saccharomices boulardii DBVPG 6763, Abela Pharm, Serbia) in everyday pediatric practice.
Methods. The study was planned as a cross-sectional study of pediatricians work in primary health care in the Republic of Serbia.
Results. The research covered 3 461 subjects which received this probiotic. Most subjects were of preschool age (59.98%, n = 2076), and then lower school age 7-12 years (15.00%, n = 519), while the lowest was in number of infants (13.98%, n = 484) and adolescents ( 4.11%, n = 382). Subjects were not statistically significantly different by gender. The most common indication for transcription of probiotics was associated diarrhea with antibiotics (64.69%, n = 2,239), followed by acute gastroenteritis (34.21%, n = 1184), while the other two indications were much rarer, Clostridium difficile enterocolitis (0.17%, n = 6), and Helicobacter pylori infection (0.93%, n = 32). The most commonly prescribed antibiotics to the probiotic were penicillins (59.09%, n = 2045) and cephalosporins (29.37%, n = 1,017), while macrolides, tetracyclines and sulfonamides were considerably less frequent. In 93.70% (n = 3243) is the case of Saccharomyces boulardii transcribed in the form of a capsule of 250 mg per day. Taking probiotics usually lasts 14 days (47.99%, n=1661).
Conclusion.- Pediatric aspect of the application of probiotics with monoculture Saccharomices boulardii is equally used in children of both sexes and in all age groups of children, but mostly in children between 1 and 6 years old. The most frequent indication for prescription of probiotics diarrhea associated with antibiotics and acute gastroenteritis. Probiotic is used alone or in combination with antibiotics, from the group of penicillin or cephalosporin.
References
Joint FAO/WHO Expert Consultation. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Food Agric Organ United Nations World Heal Organ (Fao Who) [Internet]. 2001;(October):1–34. Available from: http://scholar.google.com/ scholar?hl=en&btnG=Search&q=intitle:Health+and+Nutritional+Properties+of+Probiotics+in+Food+including+Powder+Milk+with+Live+Lactic+Acid+Bacteria#2%5Cnhttp://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Health+and+Nutrit
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol [Internet]. 2014;11(August 2014):9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24912386
Łukaszewicz M. Saccharomyces cerevisiae var. boulardii – Probiotic Yeast. Probiotics [Internet]. 2012;(March):385–98. Available from: http://cdn.intechopen.com /pdfs/39643/InTech-Saccharomyces_cerevisiae_var_ boulardii_probiotic_yeast.pdf
Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res [Internet]. 1986;20(2):192–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3080730
Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, Keates S, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression. Biochem Biophys Res Commun. 2006;343(1):69–76.
Buts J-P, Bernasconi P, Vaerman J-P, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated withSaccharomyces boulardii. Dig Dis Sci [Internet]. 1990;35(2):251–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2302983
McFarland L V. Systematic review and meta-analysis of saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202–22.
Sorini C, Falcone M. Shaping the (auto)immune response in the gut: the role of intestinal immune regulation in the prevention of type 1 diabetes. Am J Clin Exp Immunol [Internet]. 2013;2(2):156–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23885333%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3714176
Sundman E, Olofsson PS. Neural control of the immune system. AJP Adv Physiol Educ [Internet]. 2014;38(2):135–9. Available from: http://ajpadvan.physiology.org/cgi/doi/10.1152/advan.00094.2013
Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol [Internet]. 2011;5(2):111–25. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3296087&tool=pmcentrez&rendertype=abstract
Rajilic-Stojanovic M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996–1047.
Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: A randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583–90.
Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: A systematic review and meta-analysis. Int J Gen Med. 2016;9:27–37.
McFarland L V, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA [Internet]. 1994;271(24):1913–8. Available from: http://www.shelep.msk.ru/?page_id=197
Surawicz CM, McFarland L V, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012–7.
Allen SJ, Martinez EG, Gregorio G V, Dans LF. Probiotics for treating acute infectious diarrhoea. In: Allen SJ, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2010. p. 125. Available from: http://doi.wiley.com/10.1002/14651858.CD003048.pub3
Kurugöl Z, Koturoğlu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005;94(October 2003):44–7.
Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr. 2008;46(5):619–21.
Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069–79.
Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther [Internet]. 2015;41(12):1237–45. Available from: http://dx.doi.org/10.1111/apt.13214
Malfertheiner P, Megraud F, O’Morain CAC a., Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut [Internet]. 2012;61(5):646–64. Available from: http://dx.doi.org/10.1136/gutjnl-2012-302084%5Cnhttp://gut.bmj.com/content/61/5/646.abstract
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut [Internet]. 2017;66(1):6–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27707777
Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Krabshuis J, et al. Probiotics and prebiotics. Probiotics prebiotics-World Gastroenterol Organ Glob Guidel [Internet]. 2011;(October):1–28. Available from: http://www.worldgastroenterology.org /assets/export/userfiles/Probiotics_FINAL_20110116.pdf
Dragana Skokovic-Sunjic. Clinical Guide to PROBIOTIC SUPPLEMENTS AVAILABLE IN CANADA: 2016 Edition. 2016;
Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7(4).
Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr [Internet]. 2004;50(4):234–6. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=15357564&site=ehost-live
Tang N, Luo NJ. A cross-sectional study of intestinal parasitic infections in a rural district of west China. Can J Infect Dis [Internet]. 2003;14(3):159–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18159450
